Arvinas, Inc.
Arvinas is a clinical-stage biotech company dedicated to improving the lives of patients suffering from life-threatening diseases through the discovery, development, & commercialization of targeted protein degradation therapeutics. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer PROTAC® targeted protein degraders, which are designed to harness the body’s natural protein disposal system to selectively & efficiently degrade & remove disease-causing proteins. Arvinas has three clinical-stage programs and a robust preclinical pipeline of PROTAC® protein degraders.